Sunesis to present vosaroxin and cytarabine data

Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS) will present results from a Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia at the 56th American Society of Hematology Annual Meeting on December 6-9, 2014. The stock price leaped 79 cents to $2.46.